Improving the survival of transplanted fat using gene therapy
Official title: Gene Therapy-mediated Angiogenesis to Enhance Survival of Transplanted Fat
Funded at Enyx Therapeutics, LLC · NIH-10912162 · Data updated 2026-11-12
This study is testing a new way to help fat grafts last longer in surgeries by using a special treatment that encourages blood vessel growth, which could lead to better results for patients getting these types of procedures.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Enyx Therapeutics, LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 1, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $295,901 |
| NIH project number | 1R41HL170928-01A1 |
| Project ID | NIH-10912162 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals requiring soft tissue reconstruction, such as those with congenital deformities, traumatic injuries, or those undergoing oncologic surgery.
✕Less likely to help
Patients who do not require fat grafting or those with conditions that contraindicate the use of gene therapy may not benefit from this research.
What this research studies
This research focuses on enhancing the survival of autologous fat grafts, which are commonly used in reconstructive surgeries. The approach involves using a gene therapy technique to stimulate blood vessel growth in the transplanted fat, addressing a major reason for graft loss. By administering a specific adenovirus vector to the fat before transplantation, the therapy aims to significantly improve the graft's vascularization and longevity. This innovative method could lead to better outcomes for patients undergoing fat grafting procedures.
Why it matters
Potential benefit: If successful, this research could lead to more effective fat grafting techniques, resulting in improved aesthetic and functional outcomes for patients.
How similar studies have gone: While various strategies have been attempted to enhance fat graft survival, this specific gene therapy approach is novel and has not been previously tested in humans.
Where this research is happening
-
Enyx Therapeutics, LLC
New York, United States Active
Researchers
- Principal investigator: Crystal, Ronald G — Enyx Therapeutics, LLC
- Study coordinator: Crystal, Ronald G
Related research
Other NIH-funded projects on the same topics.
-
Gene therapy for osteoporosis linked to ALDH2 deficiency in postmenopausal East Asian women
A gene therapy approach is being developed to reduce osteoporosis risk in postmenopausal East Asian women who have ALDH2 deficiency and drink alcohol.
-
One-time gene therapy to prevent alcohol-related bone loss in ALDH2-deficient postmenopausal East Asian women
A single IV gene therapy aims to restore the ALDH2 enzyme to lower toxic acetaldehyde and help prevent alcohol-related bone loss in postmenopausal East Asian women with ALDH2 mutations.
-
Gene therapy to treat hereditary angioedema
This study is testing a new gene therapy that could help people with hereditary angioedema by using a modified virus to deliver a gene that makes a missing protein, aiming to reduce swelling attacks and keep you feeling better for a longer time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.